AUTHOR=Yan Ningning , Guo Sanxing , Huang Siyuan , Zhang Huixian , Li Xingya 

TITLE=The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience

JOURNAL=Frontiers in Oncology

VOLUME=Volume 14 - 2024

YEAR=2024

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1331128

DOI=10.3389/fonc.2024.1331128

ISSN=2234-943X

ABSTRACT=Background: Furmonertinib is the standard treatment option in the first-line setting for advanced non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations in China. However, there is limited real-world data available.

Methods: We conducted a retrospective study at a single center, analyzing a cohort of 73 NSCLC patients who tested positive for EGFR mutations and were treated with Furmonertinib as their initial therapy between August 2022 and December 2023. The primary endpoint was progression-free survival (PFS), with secondary endpoints including objective response rates (ORR), overall survival (OS), and safety profile.

Results: The median observation period was 9 months (95% confidence interval [CI] 8.0-20.0). The median PFS was 19.5 months (95%CI, 14.6 – 24.4). OS data was not yet mature. Univariate analysis showed no significant correlation between PFS and factors such as ECOG PS score, presence of brain or liver metastases, sex, age, EGFR mutation status, or number of metastatic sites. However, multivariate analysis indicated a potential trend towards extended PFS in patients younger than 65 years (p=0.053, 95%CI, 0.10-1.02), although the p-value was only marginally significant. The most common adverse events were diarrhea (24%), anemia (36%), and liver injury (32%); however, only four cases experienced severe adverse events.

Conclusion: In a real-world setting, Furmonertinib appears to be a favorable treatment option for EGFR-mutated patients. The manageable nature of adverse events further supports its use in clinical practice.